Feature | March 29, 2012

TAVI Study Shows Low Mortality, Improved Function at 30 Days

International multicenter ADVANCE study examines outcomes of TAVI at experienced centers

March 29, 2012 — Patients who underwent transcatheter aortic valve implantation (TAVI) at experienced medical centers had significant improvement in valve function as well as low mortality and stroke rates at 30 days, according to research presented this week at the American College of Cardiology (ACC) Annual Scientific Session.

The TAVI procedure includes inserting a bioprosthetic valve through a catheter and implanting it into a diseased native aortic valve. Because it is less invasive than surgical replacement, TAVI has been used for patients with a diseased aortic valve who cannot undergo surgery because of age, left ventricular dysfunction or the presence of coexisting conditions.

The ADVANCE study follows several trials already conducted to determine the safety and effectiveness of TAVI; however, it is the first large TAVI trial to use the Valve Academic Research Consortium’s (VARC) standards to define adverse events. It also used 44 centers that had each performed at least 40 TAVI procedures before joining the trial.

“This study evaluated real-world patients in everyday practice, allowing us to better understand the outcomes of typical use of TAVI,” said lead study author Axel Linke, professor of cardiology at the University of Leipzig Heart Center in Leipzig, Germany. “In addition, this study is one of the most rigorous TAVI studies ever conducted, and it is the first, large multicenter TAVI trial to report findings according to the new standard of evaluation, VARC.”

Between March 2010 and July 2011, a total of 1,015 high-risk patients with severe aortic stenosis were enrolled at 44 centers in 12 countries in Western Europe, Asia and South America. The patients’ mean age was 81 ± six years and 51 percent were female. The patients underwent TAVI and received the CoreValve System. They were then followed to determine the safety and efficacy of the procedure.

The study’s primary endpoint was the occurrence of major adverse cardiac and cerebrovascular events (MACCE), which is a composite of total death, stroke, heart attack and emergent cardiac surgery or percutaneous reintervention. The efficacy of the procedure was also analyzed by measuring valve function.

At the 30-day follow-up point, the researchers found that MACCE occurred in 8.3 percent of patients. The rates of total mortality and cardiac mortality were 4.5 percent and 2.2 percent, respectively, and the stroke rate was 2.9 percent. Life-threatening or disabling bleeding was observed in 4 percent of patients. The research team also found a persistent improvement in aortic valve function, accompanied by a better exercise capacity.

“The study’s conclusion is straightforward — that TAVI is effective and is associated with low mortality in the presence of an improvement in symptoms,” said Linke. “We included patients that were considered high operative risk and non-operable, and they definitely showed symptom improvement. The procedure provided great relief for the patients, as they did much better after implantation.”

The study was funded by Medtronic Inc. Linke disclosed that he is a consultant to Medtronic.

For more information: www.acc.org

Related Content

Alabama Medical Center First in Southeast to Offer CoreValve Evolut Pro TAVR Device
News | Heart Valve Technology| April 20, 2017
The Structural Heart Program at Princeton Baptist Medical Center, (Birmingham, Ala.) recently became the first center...
Updated AATS Guidelines Help Cardiovascular Surgeons Navigate Challenges of Managing Ischemic Mitral Regurgitation
News | Heart Valve Technology| April 20, 2017
April 20, 2017 — Mitral regurgitation can occur in up to 50 percent of patients with ischemic heart disease and even
USC Study Finds Potassium-Rich Diet Can Lower Blood Pressure
News | Hypertension| April 19, 2017
Eating potassium-rich foods like sweet potatoes, avocados, spinach, beans, bananas and even coffee could be key to...
3-D-printed Model of Stenotic Intracranial Artery Enables Vessel-Wall MRI Standardization
News | 3-D Printing| April 18, 2017
A collaboration between stroke neurologists at the Medical University of South Carolina (MUSC) and bioengineers at the...
3-D Printed Patch Can Help Mend a ‘Broken’ Heart

This photo shows the 3D-bioprinted cell patch in comparison to a mouse heart. When the patch was placed on a live mouse following a simulated heart attack, the researchers saw significant increase in functional capacity after just four weeks. Image courtesy of Patrick O’Leary, University of Minnesota.

News | Stem Cell Therapies| April 18, 2017
April 18, 2017 — A team of biomedical engineering researchers, led by the University of Minnesota, has created a revo
University of California Study Searches for Consistent CT Dose Best Practices
News | Radiation Dose Management| April 17, 2017
A new study led by UC San Francisco has found that radiation doses can be safely and effectively reduced – and more...
Study Finds Significant Variability in Doctors Angioplasty Death Rates
News | Cath Lab| April 17, 2017
Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as...
Grey Hair Linked With Increased Heart Disease Risk in Men
News | Cardiac Diagnostics| April 14, 2017
Grey hair has been linked with an increased risk of heart disease in men, in research presented recently at EuroPrevent...
An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS| April 14, 2017
April 14, 2017 — The Heart Rhythm Society (HRS) has announced its late-breaking clinical trials at its annual meeting
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
Overlay Init